Drugs / VLPONC-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06736379 | May 2025 → Dec 2027 expected | head and neck squamous cell carcinoma, oral cavity carcinoma | VLP Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VLPONC-01 | “The study is an Open label, Phase I study to determine the safety of IT injected VLPONC-01 as a therapeutic agent” NCT06736379 ↗ |
| Modality | Small activating RNA (saRNA) | “VRP-encapsulated saRNA encoding IL-12” NCT06736379 ↗ |
| Route | Other | “Weekly IT injections of 1 x 10^9 viral particles of VLPONC-01” NCT06736379 ↗ |